478132-53-5

Upstream product

• 23244-88-4 1H-indazol-6-ol 
• 210580-75-9 AL-34662 
• 144-55-8 sodium hydrogencarbonate 
• 501-53-1 benzyl chloroformate 
• 1004994-35-7 1-(1-acetoxy-2(S)-(benzyloxycarbonyl)amino)propyl-6-benzyloxyindazole 
• 210581-14-9 (R)-1-(6-benzyloxy-indazol-1-yl)-propan-2-ol 
• 874668-62-9 6-(benzyloxy)1-H-indazole 
• 1004994-36-8 (S)-1-(2-(benzyloxycarbonyl)amino)propyl-6-benzyloxyindazole 

Downstream Products

• 854416-61-8 [(S)-2-(7-Bromo-6-hydroxy-indazol-1-yl)-1-methyl-ethyl]-carbamic acid benzyl ester 
• 874668-74-3 [(S)-2-(6-Methoxy-indazol-1-yl)-1-methyl-ethyl]-carbamic acid benzyl ester 
• 853921-69-4 [(S)-2-(6-hydroxy-7-hydroxymethyl-indazol-1-yl)-1-methylethyl]-carbamic acid benzyl ester 
• 874668-76-5 [(S)-2-(7-Fluoro-6-hydroxy-indazol-1-yl)-1-methyl-ethyl]-carbamic acid benzyl ester 
• 874668-77-6 [(S)-2-(7-Chloro-6-hydroxy-indazol-1-yl)-1-methyl-ethyl]-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Two-step N-acylindazole to N-alkylindazole reduction. Further synthetic studies on the serotonergic agonist AL-34662

A synthesis of the title compound, operable on kilogram scale, employs reductive acetylation of an N-acylindazole to give a hemiaminal acetate followed by deacetoxylation to the corresponding N-alkylindazole.

PROCESS FOR PREPARING PYRANOINDAZOLE SEROTONERGIC RECEPTOR AGONISTS

Described are methods of making pyranoindazoles comprising reacting with a reducing agent a protected halohydrin comprising a secondary carbamate to form a pyranoindazole. In preferred embodiments the secondary carbamate is a benzyl carbamate. Also prefer

INTERMEDIATES AND METHODS FOR SEROTONERGIC AGONIST SYNTHESIS

Disclosed is a method of making a 1-alkylindazole comprising reacting a 1-acylindazole with a first reducing agent, and contacting the resulting mixture with an acid anhydride or acyl halide, and with pyridine or a 4-dialkylaminopyridine or a combination

1-((S)-2-aminopropyl)-1H-indazol-6-ol: A potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity

Serotonin 5-HT2 receptor agonists have been identified as a potential new class of agents for the treatment of ocular hypertension and glaucoma. The initially reported tryptamine analogues displayed either poor solution stability, potent centra

Pyrazolo[3,4-e]benzoxazoles for the treatment of glaucoma

Pyrazolo[3,4-e]benzoxazoles and analogues thereof for lowering intraocular pressure and treating glaucoma are disclosed.

SUBSTITUTED FURO[2,3-G] INDAZOLES FOR THE TREATMENT OF GLAUCOMA

Substituted furo[2,3-g]indazoles for lowering intraocular pressure and treating glaucoma are disclosed.

Pyranoindazoles and their use for the treatment of glaucoma

Pyranoindazoles are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions containing one or more of the compounds of the prese

PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA

Pyranoindazoles are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions containing one or more of the compounds of the prese